Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of Wee1 degradation: Amplified proximity luminescence-based biochemical assay to identify inhibitors of residues 1-40 of amyloid beta
Assay data:2 Active, 2 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Chemical optimization of in vitro pharmacology and DMPK properties of the highly selective mAChR 4 (M4) Positive Allosteric Modulator (PAM) Series with Greatly Improved Human Receptor Activity (hM3 CounterScreen)
Assay data:10 Tested
SummaryPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Late stage counterscreen assay for the probe development effort to identify inhibitors of insulin-degrading enzyme (IDE): Luminescence-based cell-based dose response assay to identify compounds that are cytotoxic to HEK cells
Assay data:2 Active, 32 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same Project
Summary of probe development efforts to identify activators of insulin-degrading enzyme (IDE)
Late stage assay provider counterscreen assay for the probe development effort to identify activators of insulin-degrading enzyme (IDE): Fluorescence-based IDE activity assay using a fluorogenic peptide substrate (FRET1) to identify fluorescent artifacts
Assay data:1 Active, 9 Tested
Counterscreen for IDE inhibitors: Luminescence-based cell-based high throughput assay to identify cytotoxic compounds using HEK cells
Assay data:334 Active, 1179 Tested
Late stage assay provider counterscreen assay for the probe development effort to identify activators of insulin-degrading enzyme (IDE): Fluorescence polarization-based biochemical dose-response assay for activators of wild-type (WT) recombinant IDE
Assay data:3 Tested
Late stage counterscreen assay for the probe development effort to identify inhibitors of insulin-degrading enzyme (IDE): fluorescence polarization-based biochemical dose response assay to identify fluorescent artifacts and/or optically active compounds
Assay data:1 Active, 32 Tested
Late stage counterscreen assay for the probe development effort to identify inhibitors of insulin-degrading enzyme (IDE): Fluorescence polarization-based biochemical dose response assay for inhibitors of recombinant IDE
Assay data:9 Active, 32 Tested
Counterscreen for IDE activators: Fluorescence polarization-based biochemical high throughput dose response assay for activators of recombinant IDE
Assay data:18 Active, 231 Tested
Counterscreen for IDE activators: Fluorescence polarization-based biochemical high throughput dose response assay to identify fluorescent artifacts and/or optically active compounds
Assay data:16 Active, 3 Activity ≤ 1 µM, 231 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same Project
Counterscreen for activators of insulin-degrading enzyme (IDE): fluorescence-based cell-based high throughput dose response LDH release assay to identify compounds that are cytotoxic to HEK cells or compromise cell membrane permeability
Assay data:30 Active, 231 Tested
Fluorescence polarization-based cell-based high throughput dose response assay to identify activators of insulin-degrading enzyme (IDE)
Assay data:32 Active, 1 Activity ≤ 1 µM, 231 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Dose Response: Fluorescence polarization-based cell-based high throughput dose response assay for inhibitors of insulin-degrading enzyme (IDE)
Assay data:44 Active, 1 Activity ≤ 1 µM, 127 Tested
Fluorescence polarization-based cell-based high throughput confirmation assay for inhibitors of insulin-degrading enzyme (IDE)
Assay data:598 Active, 1179 Tested
Late stage assay provider counterscreen for the probe development effort to identify IDE inhibitors: Fluorescence-based IDE activity assay using a fluorogenic peptide substrate (FRET1) to identify fluorescent artifacts
Assay data:10 Active, 2 Activity ≤ 1 µM, 55 Tested
Late stage assay provider counterscreen for the probe development effort to identify IDE inhibitors: TR-FRET-based IDE activity assay to identify inhibitors of recombinant IDE's degradation of insulin
Assay data:3 Active, 17 Tested
Inhibition of human amyloid beta (1 to 42) aggregation at 100 uM measured after 72 hrs by by Thioflavin T-based fluorometric assay
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of amyloid beta (1 to 42) (unknown origin) aggregation at 50 uM measured after 3 hrs by Thioflavin T-based fluorometric assay
Assay data:2 Tested
Inhibition of human BuChE assessed as hydrolytic activity using butyrylthiocholine iodide as substrate measured for 15 mins by Ellmans assay
Assay data:1 Active, 3 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on